Market Overview

UPDATE: BMO Capital Markets Terminates Coverage on Amerigroup Corporation

Share:
Related AGP
Amerigroup Sells Virginia Health Plan to Inova
Express Scripts Earnings Preview: More Strong Revenue Expected on Acquisition

In a report published Friday, BMO Capital Markets terminated its coverage on Amerigroup Corporation (NYSE: AGP).

BMO Capital noted, “We are dropping coverage of Amerigroup (AGP) owing to its acquisition by WellPoint. The transaction closed on Tuesday, December 24. The shares of AGP have been rated Market Perform since July 9, 2012. Investors should no longer rely on BMO Capital Markets Research for an investment recommendation on Amerigroup.”

Amerigroup Corporation closed on Thursday at $91.70.

Latest Ratings for AGP

DateFirmActionFromTo
Dec 2012Deutsche BankTerminatesHold
Dec 2012WedbushTerminates
Jul 2012Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for AGP
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Termination Analyst Ratings

 

Related Articles (AGP)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TVPTImperial CapitalDowngrades15.8
ACORGoldman SachsDowngrades10.0
APTIJefferiesDowngrades38.0
BCOVB. Riley FBRUpgrades12.0
CAMPFirst AnalysisDowngrades22.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Aegis Capital Reiterates Buy Rating, $25 PT on Synergy Pharmaceuticals

Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid